

Partners in the Fight against Malaria



Doing our part: Efforts of the research-based pharmaceutical industry to fight malaria

Available treatments



Artemisinin-based combination therapy (ACT) is the best available treatment to treat malaria

Thanks to a successful partnership with Medicines for Malaria Venture (MMV), a dispersible version is now available for children

Injectable artesunate is recommended for severe malaria

R&D for improved treatments and vaccines



37 R&D projects for improved treatments:

7 R&D projects are in phase I or II
4 R&D projects are in phase III or IV

3 R&D projects for vaccines
1 promising vaccine (RTS, S/AS01E) is currently under evaluation at European Medicines Agency (EMA)

Expanding access to care



We are working with partners to:

Increase availability of antimalarials

Share scientific knowledge and scaling-up manufacturing capabilities in emerging markets

Strengthen health systems by equipping hospitals, and supporting provision of safe water and sanitation

Develop training tools and education initiatives adapted to the general public and to all actors in the health chain

Train healthcare workers to improve their knowledge and ability to identify malaria in early stages

Reduce stock shortages and deliver essential medicines to remote health centers via mHealth programs

Fight fake and substandard medicines

To download the full infographic *Partners in the Fight against Malaria*:

www.ifpma.org/fileadmin/content/Publication/2015/IFPMA_Infographic_World_Malaria_Day_2015.pdf

References:

IFPMA Health Partnerships Directory

IFPMA, Pharmaceutical R&D Projects to Prevent and Control Neglected Conditions, 2014 Status report on pharmaceutical R&D to address diseases disproportionately affecting people in low- and middle-income countries, January 2015



IFPMA